Edgar Filing: NEOPROBE CORP - Form 8-K

NEOPROBE CORP Form 8-K April 30, 2007

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 8-K

CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported)

April 25, 2007

NEOPROBE CORPORATION

(Exact name of registrant as specified in its charter)

Delaware (State or other jurisdiction of incorporation) 0-26520 (Commission File Number)

31-1080091

(IRS Employer Identification No.)

425 Metro Place North, Suite 300, Columbus, Ohio (Address of principal executive offices)

43017 (Zip Code)

Registrant's telephone number, including area code

(614) 793-7500

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Edgar Filing: NEOPROBE CORP - Form 8-K

Item 2.02.

Results of Operations and Financial Condition.

On April 30, 2007, Neoprobe Corporation (the "Company") issued a press release regarding its consolidated financial results for the quarter ended March 31, 2007. A copy of the Company's April 30, 2007, press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information contained in Item 2.02 of this Current Report on Form 8-K, including exhibit 99.1 hereto, shall not be treated as "filed" for purposes of the Securities Exchange Act of 1934, as amended.

Item Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;
 5.02. Compensatory Arrangements of Certain Officers.

On April 25, 2007, Carl M. Bosch, the Company's Vice President of Research and Development, and a named executive officer in the Company's 2006 Annual Report on Form 10-KSB, submitted his resignation as an officer of the Company.

Statements contained or incorporated by reference in this Current Report on Form 8-K which relate to other than strictly historical facts, such as statements about the Company's plans and strategies, expectations for future financial performance, new and existing products and technologies, and markets for the Company's products, are forward-looking statements. The words "believe," "expect," "anticipate," "estimate," "project," and similar expressions identify forward-looking statements that speak only as of the date hereof. Investors are cautioned that such statements involve risks and uncertainties that could cause actual results to differ materially from historical or anticipated results due to many factors including, but not limited to, the Company's continuing operating losses, uncertainty of market acceptance, reliance on third party manufacturers, accumulated deficit, future capital needs, uncertainty of capital funding, dependence on limited product line and distribution channels, competition, limited marketing and manufacturing experience, and other risks detailed in the Company's most recent Annual Report on Form 10-KSB and other Securities and Exchange Commission filings. The Company undertakes no obligation to publicly update or revise any forward-looking statements.

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number Exhibit Description

99.1 Neoprobe Corporation press release dated April 30, 2007, entitled "Neoprobe Announces

First Quarter Results."

2

Edgar Filing: NEOPROBE CORP - Form 8-K

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Neoprobe Corporation

Date: April 30, 2007 By: /s/ Brent L. Larson

Brent L. Larson, Vice President, Finance and

Chief Financial Officer

3